Hanna Berak

813 total citations
41 papers, 191 citations indexed

About

Hanna Berak is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Hanna Berak has authored 41 papers receiving a total of 191 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Hepatology, 26 papers in Epidemiology and 10 papers in Infectious Diseases. Recurrent topics in Hanna Berak's work include Hepatitis C virus research (39 papers), Liver Disease Diagnosis and Treatment (20 papers) and Hepatitis B Virus Studies (14 papers). Hanna Berak is often cited by papers focused on Hepatitis C virus research (39 papers), Liver Disease Diagnosis and Treatment (20 papers) and Hepatitis B Virus Studies (14 papers). Hanna Berak collaborates with scholars based in Poland, Switzerland and Vietnam. Hanna Berak's co-authors include Tomasz Laskus, Kamila Caraballo Cortés, Marek Radkowski, Karol Perlejewski, Iwona Bukowska‐Ośko, Agnieszka Pawełczyk, Robert Flisiak, Dorota Zarębska‐Michaluk, Ewa Janczewska and Andrzej Horban and has published in prestigious journals such as PLoS ONE, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Hanna Berak

34 papers receiving 190 citations

Peers

Hanna Berak
Nobutoshi Komatsu Japan
Karin S. Ku United States
Dorota Dybowska Poland
Zehui Yan China
Ofer Ben‐Moshe Israel
H.W. Reesink Netherlands
Stefan Zeuzem Germany
Zu‐Jiang Yu China
Atsushi Ozasa Japan
Gururaj Kalkeri United States
Nobutoshi Komatsu Japan
Hanna Berak
Citations per year, relative to Hanna Berak Hanna Berak (= 1×) peers Nobutoshi Komatsu

Countries citing papers authored by Hanna Berak

Since Specialization
Citations

This map shows the geographic impact of Hanna Berak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hanna Berak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hanna Berak more than expected).

Fields of papers citing papers by Hanna Berak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hanna Berak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hanna Berak. The network helps show where Hanna Berak may publish in the future.

Co-authorship network of co-authors of Hanna Berak

This figure shows the co-authorship network connecting the top 25 collaborators of Hanna Berak. A scholar is included among the top collaborators of Hanna Berak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hanna Berak. Hanna Berak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pawłowski, Tomasz, Marek Radkowski, Karol Perlejewski, et al.. (2025). Direct-acting antivirals (DAA) positively affect depression and cognitive function in patients with chronic hepatitis C. PLoS ONE. 20(4). e0320221–e0320221.
2.
3.
Zarębska‐Michaluk, Dorota, Małgorzata Pawłowska, Magdalena Tudrujek‐Zdunek, et al.. (2025). Sex-related differences in patients with chronic hepatitis C infection treated with direct-acting antiviral drugs. World Journal of Hepatology. 17(6). 105899–105899.
4.
Zarębska‐Michaluk, Dorota, Michał Kukla, Dorota Dybowska, et al.. (2024). Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices. Pharmacological Reports. 76(5). 1114–1129. 1 indexed citations
5.
Piekarska, Anna, Hanna Berak, Włodzimierz Mazur, et al.. (2024). Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide. Clinical and Experimental Hepatology. 10(3). 165–169.
6.
Flisiak, Robert, Dorota Zarębska‐Michaluk, Hanna Berak, et al.. (2024). Treatment with Sofosbuvir/Velpatasvir of the most difficult to cure HCV-infected population. Polskie Archiwum Medycyny Wewnętrznej. 134(2). 2 indexed citations
7.
Tronina, Olga, Dorota Zarębska‐Michaluk, Beata Lorenc, et al.. (2023). Real-world effectiveness of genotype-specific and pangenotypic direct-acting antivirals in HCV-infected patients with renal failure. Clinical and Experimental Hepatology. 9(4). 320–334. 1 indexed citations
8.
Flisiak, Robert, Dorota Zarębska‐Michaluk, Hanna Berak, et al.. (2023). Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals. Clinical and Experimental Hepatology. 9(3). 193–201. 4 indexed citations
9.
Tronina, Olga, Dorota Zarębska‐Michaluk, Dorota Dybowska, et al.. (2023). Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens. Viruses. 15(3). 677–677. 3 indexed citations
10.
Radkowski, Marek, Hanna Berak, Andrzej Horban, et al.. (2023). Depression and Cognitive Dysfunction in Patients with Chronic Hepatitis C: Correlation with Viral Replication in the Peripheral Blood Mononuclear Cells and Cytokines in Serum. International Journal of Molecular Sciences. 24(20). 15351–15351. 1 indexed citations
11.
Berak, Hanna, et al.. (2023). Double Positive CD4+CD8+ (DP) T-Cells Display Distinct Exhaustion Phenotype in Chronic Hepatitis C. Cells. 12(10). 1446–1446. 4 indexed citations
12.
Pazgan−Simon, Monika, Jerzy Jaroszewicz, Krzysztof Simon, et al.. (2023). Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland. Journal of Personalized Medicine. 13(7). 1111–1111. 3 indexed citations
13.
Zarębska‐Michaluk, Dorota, Robert Flisiak, Ewa Janczewska, et al.. (2023). Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?. Antiviral Research. 220. 105742–105742. 1 indexed citations
14.
Dybowska, Dorota, Dorota Zarębska‐Michaluk, Piotr Rzymski, et al.. (2023). Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders. World Journal of Gastroenterology. 29(25). 4085–4098. 6 indexed citations
15.
Zarębska‐Michaluk, Dorota, Piotr Rzymski, Beata Lorenc, et al.. (2023). Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era. World Journal of Gastroenterology. 29(13). 2015–2033. 10 indexed citations
16.
Zarębska‐Michaluk, Dorota, Jerzy Jaroszewicz, Magdalena Tudrujek‐Zdunek, et al.. (2022). Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients. World Journal of Gastroenterology. 28(45). 6380–6396. 5 indexed citations
17.
Zarębska‐Michaluk, Dorota, Jerzy Jaroszewicz, Anna Parfieniuk‐Kowerda, et al.. (2022). Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection. Journal of Clinical Medicine. 11(2). 389–389. 8 indexed citations
18.
19.
20.
Cortés, Kamila Caraballo, Osvaldo Zagordi, Karol Perlejewski, et al.. (2014). Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome. BMC Infectious Diseases. 14(1). 389–389. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nobutoshi Komatsu Breakdown of academic impact, for papers by Karin S. Ku Breakdown of academic impact, for papers by Dorota Dybowska Breakdown of academic impact, for papers by Zehui Yan Breakdown of academic impact, for papers by Ofer Ben‐Moshe Breakdown of academic impact, for papers by H.W. Reesink Breakdown of academic impact, for papers by Stefan Zeuzem Breakdown of academic impact, for papers by Zu‐Jiang Yu Breakdown of academic impact, for papers by Atsushi Ozasa Breakdown of academic impact, for papers by Gururaj Kalkeri
Rankless by CCL
2026